SweDeliver
Research forum in drug delivery, focusing on new strategies for parenteral, oral and pulmonary drug delivery.
News
- Meet our partners: Apotek Produktion & Laboratorier AB (APL) 2023-05-30
- In focus: Anna Simonsson • An alumna has found her way home 2023-05-30
- AI and self-learning machines rewriting the pharmaceutical map 2023-05-29
- All set for new course Pharmaceutical aerosols 2023-05-25
- Best Paper Award for SweDeliver publication 2023-05-23
Seminars & Events
Researcher Profile
Anna Simonsson

"My time as a PhD student is an entirely positive experience"
New Course Autumn 23
Pharmaceutical Aerosols

"We have succeeded in enrolling the finest in our field"
Best Paper Award
To Alexandra teleki a o

Intrinsic lipolysis rate for systematic design of lipid-based formulations
Meet our partners
Apotek Produktion & Lab.

6 Questions & 6 Answers with Christina Holmberg at APL
This is SweDeliver
SweDeliver is a world leading research and competence centre in Drug Delivery. Many novel molecules in the drug discovery and development pipeline are biological compounds such as proteins, peptides and RNA. These display problems of poor solubility, membrane permeability and low bioavailability. Thus, the Drug Delivery area is today facing tremendous challenges to develop new drug therapies.
SweDeliver was established in response to these challenges. Based on a multi-disciplinary collaboration between academia and industry with financial support from Vinnova (Sweden’s Innovation Agency), the Faculty of Pharmacy at Uppsala University is the academic hub of the Centre with 16 industrial partners contributing expertise and research infrastructure as well as industrial perspectives and needs within the three main research areas of the Centre.
SweDeliver has prioritized to focus on outstanding research challenges within
- Parenteral Drug Delivery
- Oral Drug Delivery
- Pulmonary Drug Delivery
The research will ultimately lead to development of new and improved drug therapies with respect to both efficacy and patient safety. The Centre will also further support the strong research environment and the drug delivery ecosystem in the Nordic region.
